Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy

摘要: Abstract Introduction Nivolumab is effective in the treatment of previously treated patients with advanced NSCLC. However, its radiological evaluation challenging because atypical patterns response such as pseudoprogression. We examined characteristics and outcomes NSCLC who were with nivolumab experienced development Methods conducted a 15-center retrospective cohort study received nivolumab monotherapy. For showed pseudoprogression, we defined progression-free survival 1 (PFS1) time to Response Evaluation Criteria Solid Tumors–defined first progressive disease 2 (PFS2) second or death. Results Among 542 included, 20% 53% typical progression, respectively. Of 14 (3%) most (n = 10) within 3 months treatment. The median PFS1 PFS2 1.0 7.3 months, was significantly shorter pseudoprogression than PFS (p  Conclusions Pseudoprogression uncommon, duration that response. benefit markedly better progression. Further research required elucidate mechanisms underlying